Loading...
•
Mar 31, 2021
ANI Pharmaceuticals Q1 2021 Earnings Report
Reported net revenues of $54.5 million, net income of $0.1 million, and diluted earnings per share of $0.01 for the first quarter of 2021.
Key Takeaways
ANI Pharmaceuticals reported first quarter 2021 results with net revenues of $54.5 million and net income of $0.1 million. The company is progressing with the Cortrophin Gel sNDA re-filing and the acquisition of Novitium Pharma, while also expanding its branded products portfolio.
Net revenues for Q1 2021 were $54.5 million.
Net income for Q1 2021 was $0.1 million, with diluted earnings per share of $0.01.
Adjusted non-GAAP EBITDA for Q1 2021 was $18.9 million, and adjusted non-GAAP diluted earnings per share was $1.04.
The company is on track for Cortrophin® Gel sNDA re-filing in Q2 2021.
Revenue by Segment
Forward Guidance
The company expects the Novitium transaction and the market opportunity for Cortrophin to be transformational for ANI.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...